Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell

The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).

The study found that aTac-BEAM-ASCT was safe and well tolerated in these patients. 

Some background

The BEAM regimen has long been the standard chemotherapy combination for cHL. However, a high number of patients with cHL experience relapse (worsening of the disease) or refractory (not responsive) disease to standard treatments. After high-dose chemotherapy, patients often receive an ASCT. This involves transplanting healthy cells taken from the same patient back to restore healthy blood cells.

Immunotherapy is a type of cancer treatment that boosts the body’s natural defenses to fight cancer. RAI attaches a radioactive molecule to an immune protein to target and kill cancer cells. HL expresses a protein called CD25 on cancer cells. It remains unclear if attaching a radioactive molecule to immune cells that attack CD25 (aTac) followed by BEAM and ASCT improves the outcomes of patients with r/r cHL.

Methods & findings

This study included 22 patients with high-risk r/r cHL. All patients received aTac followed by BEAM and ASCT. The average follow-up period was 59.2 months.

95% of patients responded to treatment and 91% had a complete response (complete disappearance of cancer). 32% of patients relapsed at an average of 3.7 months after ASCT. 

68% of patients were estimated to survive without cancer worsening for 5 years. 95% of patients were estimated to be alive after 5 years. 

The most common side effects were an inflamed or sore mouth (95%), digestive problems (27%), and liver problems (23%).

The bottom line

This study concluded that aTac RAS followed by BEAM and AHCT was a safe and tolerated treatment in patients with high-risk r/r cHL.

The fine print

This study reported on a small number of patients who were treated at various dose levels of radiation. These results require confirmation with a larger number of patients with high-risk r/r HL.

Published By :

Blood advances

Date :

Oct 12, 2021

Original Title :

Anti-CD25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma.

click here to get personalized updates